In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Buy rating on Penumbra (PEN – Research Report), with a price target of ...

BTIG analyst David Larsen raised the firm’s price target on Consensus Cloud (CCSI) to $37 from $32 and keeps a Buy rating on the shares. The ...

BTIG analyst Janine Stichter adjusted the price target for Steven Madden (NASDAQ: NASDAQ:SHOO) shares to $46.00, down from ...

BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain ...

Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note issued to investors on Tuesday, January 28th. BTIG Research analyst C.

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am. Discover outperforming stocks and invest smarter with ...

But before that let's have a chartist view from BTIG's technical guru Jonathan Krinsky. He notes that the S&P 500's rally off this week's lows is quite impressive and sets up the stock barometer ...

Investing.com -- BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025. The brokerage ...